A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab (AIN457) in Patients With Giant Cell Arteritis (TitAIN)
Phase of Trial: Phase II
Latest Information Update: 25 Jul 2019
Price : $35 *
At a glance
- Drugs Secukinumab (Primary) ; Prednisolone
- Indications Giant cell arteritis
- Focus Therapeutic Use
- Acronyms TitAIN
- Sponsors Novartis; Novartis Pharmaceuticals
- 17 Jul 2019 Planned End Date changed from 30 Aug 2021 to 31 Dec 2021.
- 04 Feb 2019 Status changed from not yet recruiting to recruiting.
- 13 Dec 2018 New source identified and integrated (European Clinical Trials Database)